Pleiotropic actions of PPARγ activators thiazolidinediones in cardiovascular diseases

Current Pharmaceutical Design

Volumn 10, Issue 22, 2004, Pages 2779-2786

  Takano, Hiroyuki ^a   Hasegawa, Hiroshi ^a   Zou, Yunzeng ^a   Komuro, Issei ^a  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Atherosclerosis; Cardiac hypertrophy; Glitazones; Heart failure; Myocardial infarction; PPAR ; Th1 Th2; Thiazolidinedione

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANGIOTENSIN; ANTIDIABETIC AGENT; CELL NUCLEUS RECEPTOR; CYTOKINE; DELTA12 PROSTAGLANDIN J2; FENOFIBRATE; GLUCOSE; INSULIN; ISOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PROSTAGLANDIN D2; RETINOID X RECEPTOR; ROSIGLITAZONE; TRANSCRIPTION FACTOR; TROGLITAZONE;

ADIPOCYTE; ADIPOSE TISSUE; ALZHEIMER DISEASE; ATHEROSCLEROSIS; BREAST CANCER; CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; CELL TYPE; COLORECTAL CANCER; DIABETES MELLITUS; DRUG MECHANISM; ENTERITIS; GLUCOSE HOMEOSTASIS; HEART FAILURE; HEART INFARCTION; HEART OUTPUT; HEART STROKE VOLUME; HUMAN; INSULIN SENSITIVITY; MACROPHAGE ACTIVATION; MEDICAL RESEARCH; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN ISOLATION; RAT; REVIEW; RHEUMATOID ARTHRITIS;

ARTERIOSCLEROSIS; HEART FAILURE, CONGESTIVE; HUMANS; LIGANDS; MODELS, BIOLOGICAL; MUTATION; MYOCARDIAL INFARCTION; RECEPTORS, CYTOPLASMIC AND NUCLEAR; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS;

EID: 4344692482     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043383719     Document Type: Review

References (98)

1. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990; 347: 645-50.
2. Jiang C, Ting AT, Seed B. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 1998; 391: 82-6.
3. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome prolifcrator-activated receptor-γ is a negative regulator of macrophage activation. Nature 1998; 391: 79-82.
4. Marx N, Schonbeck U, Lazar MA, Libby P, Plutzky J. Peroxisome proliferator-activatcd receptor γ activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res 1998; 83: 1097-103,
5. Iijima K, Yoshizumi M, Ako J, Eto M, Kim S, Hashimoto M, et al. Expression of peroxisome proliferator-activated receptor γ (PPARγ) in rat aortic smooth muscle cells. Biochem Biophys Res Commun 1998; 247: 353-6.
6. Benson S, Wu J, Padmanabhan S, Kurtz TW, Pershadsingh HA. Peroxisome proliferator-activated receptor (PPAR)-γ expression in human vascular smooth muscle cells: inhibition of growth, migration, and c-fos expression by the peroxisome proliferator-activated receptor (PPAR -γ activator troglitazone. Am J Hypertens 2000; 13: 74-82.
7. Takano H, Nagai T, Asakawa M, Toyozaki T, Oka T, Komuro I, et al. Peroxisome proliferator-activated receptor activators inhibit lipopolysaccharide-induced tumor necrosis factor-α expression in neonatal rat cardiac myocytes. Circ Res 2000; 87: 596-602.
8. Marx N, Sukhova G, Murphy C, Libby P, Plutzky J. Macrophage in human atheroma contain PPARγ: Differentiation-dependent peroxisomal proliferator-activated receptor γ (PPARγ) expression and reduction of MMP-9 activity through PPARγ activation in mononuclear phagocytes in vitro. Am J Pathol 1998; 153: 17-23.
9. Ricote M, Huang J, Fajas L, Li A, Welch J, Najib J, et al. Expression of the peroxisome proliferator-activated receptor γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci USA 1998; 95: 7614-9.
10. Hu E, Kim JB, Sarraf P, Spiegelman BM. Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARγ. Science 1996; 274: 2100-3.
11. Zhang B, Berger J, Zhou G, Elbrecht A, Biswas S, White-Carrington S, et al. Insulin- and mitogen-activated protein kinase-mediated phosphorylation and activation of peroxisome proliferator-activated receptor γ. J Biol Chem 1996; 271: 31771-4.
12. Camp HS, Tafuri SR, Leff T. c-Jun N-terminal kinase phosphorylates peroxisome proliferator-activated receptor-γ1 and negatively regulates its transcriptional activity. Endocrinology 1999; 140: 392-7.
13. Dowell P, Ishmael JE, Avram D, Peterson VJ, Nevrivy DJ, Leid M. P300 functions as a coactivator for the peroxisome proliferator-activated receptor α. J Biol Chem 1997; 272: 33435-43.
14. Gerritsen ME, Williams AJ, Neish AS, Moore S, Shi Y, Collins T. CREB-binding protein/p300 are transcriptional coactivators of p65. Proc Natl Acad Sci USA 1997; 94: 2927-32.
15. Mizukami J, Taniguchi T. The antidiabetic agent thiazolidinedione stimulates the interaction between PPARγ and CBP. Biochem Biophys Res Commun 1997; 240: 61-4.
16. Zhu Y, Qi C, Calandra C, Rao MS, Reddy JK. Cloning and identification of mouse steroid receptor coactivator-1 (mSRC-1), as a coactivator of peroxisome proliferator-activated receptor γ. Gene Expr 1996; 6: 185-95.
17. Nolte RT, Wisely GB, Westin S, Cobb JE, Lambert MH, Kurokawa R, et al. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ. Nature 1998; 395: 137-43.
18. Sheppard KA, Phelps KM, Williams AJ, Thanos D, Glass CK, Rosenfeld MG, et al. Nuclear integration of glucocorticoid receptor and nuclear factor-κB signaling by CREB-binding protein and steroid receptor coactivator-1. J Biol Chem 1998 273: 29291-4.
19. Puigserver P, Adelmant G, Wu Z, Fan M, Xu J, O'Malley B, et al. Activation of PPARγ coactivator-1 through transcription factor docking. Science 1999; 286: 1368-71.
20. Nagy L, Tontonoz P, Alvarez JGA, Chen H, Evans RM. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ. Cell 1998; 93: 229-40.
21. Tontonoz P, Nagy L, Alvarez JGA, Thomazy VA, Evans RM. PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 1998; 93: 241-52.
22. Huang JT, Welch JS, Ricote M, Binder CJ, Willson TM, Kelly C, et al. Interleukin-4-dependent production of PPAR-γ ligands in macrophages by 12/15-lipoxygenase. Nature 1999; 400: 378-82.
23. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkinson WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J Biol Chem 1995; 270: 12953-6.
24. Camp HS, Li O, Wise SC, Hong YH, Frankowski CL, Shen X, et al. Differential activation of peroxisome proliferator-activated receptor-γ by troglitazone and rosiglitazone. Diabetes 2000; 49: 539-47.
25. Sakamoto J, Kimura H, Moriyama S, Odaka H, Momose Y, Sugiyama Y, et al. Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem Biophys Res Commun 2000; 278: 704-11.
26. Okuno A, Tamemoto H, Tobe K, Ueki K, Mori Y, Iwamoto K, et al. Troglilazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 1998; 101: 1354-61.
27. Wu Z, Xie Y, Morrison RF, Bucher NLR, Farmer SR. PPARγ induces the insulin-dependent glucose transporter GLUT4 in the absence of C/EBPα during the conversion of 3T3 fibroblasts into adipocytes. J Clin Invest 1998; 101: 22-32.
28. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA. Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1997; 272: 3406-10.
29. Inoue H, Tanabe T, Umesono K. Feedback control of cyclooxygenase-2 expression through PPARγ. J Biol Chem 2000; 275: 28028-32.
30. Subbaramaiah K, Lin DT, Hart JC, Dannenberg AJ. Peroxisome proliferator-activated receptor γ ligands suppress the transcriptional activation of cyclooxygenase-2. J Biol Chem 2001; 276: 12440-8.
31. Kliewer SA, Umesono K, Noonan DJ, Heyman RA, Evans RM. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 1992; 358: 771-4.
32. Benson S, Padmanabhan S, Kurtz TW, Pershadsingh HA. Ligands for the peroxisome proliferator-activated receptor-γ and the retinoid X receptor-α exert synergistic antiproliferative effects on human coronary artery smooth muscle cells. Mol Cell Biol Res Commun 2000; 3: 159-64.
33. Uchimura K, Nakamuta M, Enjoji M, Irie T, Sugimoto R, Muta T, et al. Activation of retinoic X receptor and peroxisome proliferator-activated receptor-γ inhibits nitric oxide and tumor necrosis factor-α production in rat Kupffer cells. Hepatology 2001; 33: 91-9.
34. Marx N, Kehrle B, Kohlhammer K, Grub M, Koenig W, Hombach V, et al. PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ Res 2002; 90: 703-10.
35. Law RE, Meehan WP, Xi XP, Graf K, Wuthrich DA, Coats W, et al. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest 1996; 98: 1897-905.
36. Goetze S, Xi XP, Kawano H, Gotlibowski T, Fleck E, Hsueh WA, et al. PPAR γ-ligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells. J Cardiovasc Pharmacol 1999; 33: 798-806.
37. Hsueh WA, Jackson S, Law RE. Control of vascular cell proliferation and migration by PPAR-γ: a new approach to the macrovascular complications of diabetes. Diabetes Care 2001; 24: 392-7.
38. Takata Y, Kitami Y, Okura T, Hiwada K. Peroxisome proliferator-activated receptor-γ activation inhibits interleukin-1β-mediated platelet-derived growth factor-α receptor gene expression via CCAAT/enhancer-binding protein-δ in vascular smooth muscle cells. J Biol Chem 2001; 276: 12893-7.
39. Okura T, Nakamura M, Takata Y, Watanabe S, Kitami Y, Hiwada K. Troglitazone induces apoptosis via the p53 and Gadd45 pathway in vascular smooth muscle cells. Eur J Pharmacol 2000; 407: 227-35.
40. Aizawa Y, Kawabe J, Hasebe N, Takehara N, Kikuchi K. Pioglitazone enhances cytokine-induced apoptosis in vascular smooth muscle cells and reduces intimal hyperplasia. Circulation 2001; 104: 455-60.
41. Sugawara A, Takeuchi K, Uruno A, Ikeda Y, Arima S, Kudo M, et al. Transcriptional suppression of type 1 angiotensin II receptor gene expression by peroxisome proliferator-activated receptor-γ in vascular smooth muscle cells. Endocrinology 2001; 142: 3125-34.
42. Takeda K, Ichiki T, Tokunou T, Funakoshi Y, Iino N, Hirano K, et al. Peroxisome proliferator-activated receptor γ activators downregulate angiotensin II type 1 receptor in vascular smooth muscle cells. Circulation 2000; 102: 1834-9.
43. Tham DM, Martin-McNulty B, Wang YX, Wilson DW, Vergona R, Sullivan ME, et al. Angiotensin II is associated with activation of NF-κB-mediated genes and downregulation of PPARs. Physiol Genomics 2002; 11: 21-30.
44. Takata Y, Kitami Y, Yang ZH, Nakamura M, Okura T, Hiwada K. Vascular inflammation is negatively autoregulated by interaction between CCAAT/enhancer-binding protein-δ and peroxisome proliferator-activated receptor-γ. Circ Res 2002; 91: 427-33.
45. Jackson SM, Parhami F, Xi XP, Berliner JA, Hsueh WA, Law RE, et al. Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. Arterioscler Thromb Vasc Biol 1999; 19: 2094-104.
46. Pasceri V, Wu HD, Willerson JT, Yeh ETH. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-γ activators. Circulation 2000; 101: 235-8.
47. Lee H, Shi W, Tontonoz P, Wang S, Subbanagounder G, Hedrick CC, et al. Role of peroxisome proliferator-activated receptor α in oxidized phospholipid-induced synthesis of monocyte chemotactic protein-1 and interleukin-8 by endothelial cells. Circ Res 2000; 87: 516-21.
48. Kintscher U, Goetze S, Wakino S, Kim S, Nagpal S, Chandraratna RA, et al. Peroxisome proliferator-activated receptor and retinoid X receptor ligands inhibit monocyte chemotactic protein-1-directed migration of monocytes. Eur J Pharmacol 2000, 401: 259-70.
49. Delerive P, Martin-Nizard F, Chinetti G, Trottein F, Fruchart JC, Najib J, et al. Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res 1999; 85: 394-402.
50. Han J, Hajjar DP, Tauras JM, Feng J, Gotto AM Jr, Nicholson AC. Transforming growth factor-β1 (TGF-β1) and TGF-β2 decrease expression of CD36, the type B scavenger receptor, through mitogen-activated protein kinase phosphorylation of peroxisome proliferator-activated receptor-γ. J Biol Chem 2000; 275: 1241-6.
51. Repa JJ, Turley SD, Lobaccaro JA; Medina J, Li L, Lustig K, et al. Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science 2000; 289: 1524-9.
52. Venkateswaran A, Laffitte BA, Joseph SB, Mak PA, Wilpitz DC, Edwards PA, et al. Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha. Proc Natl Acad Sci USA 2000; 97: 12097-102.
53. Coster P, Luo Y, Wang N, Tall AR. Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. J Biol Chem 2000; 275: 28240-5.
54. Chawla A, Boisvert WA, Lee CH, Laffitte BA, Barak Y, Joseph SB, et al. A PPARγ-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell 2001; 7: 161-71.
55. Chinetti G, Lestavel S, Bocher V, Remaley AT, Neve B, Torra IP, et al. PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 2001; 7: 53-8.
56. Jiang J-G, Johnson C, Zarnegar R. PPARγ-mediated transcriptional upregulation of the hepatocyte growth factor gene promoter via a novel composite cis-acting element. J Biol Chem 2001; 276: 25049-56.
57. Taniyama Y, Morishita R, Aoki M, Nakagami H, Yamamoto K, Yamazaki K, et al. Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat and rabbit hindlimb ischemia models: preclinical study for treatment of peripheral arterial disease. Gene Ther 2001; 8: 181-9.
58. Ishibashi M, Egashira K, Hiasa K, Inoue S, Ni W, Zhao Q, et al. Antiinflammatory and antiarteriosclerotic effects of pioglitazone. Hypertension 2002; 40: 687-93.
59. Wang CH, Weisel RD, Liu PP, Fedak PW, Verma S. Glitazones and heart failure: critical appraisal for the clinician. Circulation 2003; 107: 1350-4.
60. Ogihara T, Rakugi H, Ikegami H, Mikami H, Masuo K. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertens 1995; 8: 316-20.
61. Saku K, Zhang B, Ohta T, Arakawa K. Troglitazone lowers blood pressure and enhances insulin sensitivity in Watanabe heritable hyperlipidemic rabbits. Am J Hypertens 1997; 10: 1027-33.
62. Yoshimoto T, Naruse M, Nishikawa M, Naruse K, Tanabe A, Seki T, et al. Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats. Am J Physiol 1997; 272: E989-96.
63. Diep QN, El Mabrouk M, Cohn JS, Endemann D, Amiri F, Virdis A, et al. Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-γ. Circulation 2002; 105: 2296-302.
64. Iglarz M, Touyz RM, Amiri F, Lavoie MF, Diep QN, Schiffrin EL. Effect of peroxisome proliferator-activated receptor-α and -γ activators on vascular remodeling in endothelin-dependent hypertension. Arterioscler Thromb Vasc Biol 2003; 23: 45-51.
65. Marx N, Imhof A, Froehlich J, Siam L, Ittner J, Wierse G, et al. Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease. Circulation 2003; 107: 1954-7.
66. Varo N, Vicent D, Libby P, Nuzzo R, Calle-Pascual AL, Bernal MR, et al. Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones. Circulation 2003; 107: 2664-9.
67. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002; 106: 679-84.
68. Sidhu JS, Cowan D, Kaski JC. The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. J Am Coll Cardiol 2003; 42: 1757-63.
69. Takagi T, Akasaka T, Yamamuro A, Honda Y, Hozumi T, Morioka S, et al. Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: a serial intravascular ultrasound study. J Am Coll Cardiol 2000; 36: 1529-35.
70. Takagi T, Yamamuro A, Tamita K, Yamabe K, Katayama M, Mizoguchi S, et al. Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study. Am Heart J 2003; 146: E5.
71. Mehrabi MR, Thalhammer T, Haslmayer P, Glogar HD, Wieselthaler G, Humpeler S, et al. The peroxisome proliferator-activated receptor γ (PPARγ) is highly expressed in human heart ventricles. Biomed Pharmacother 2002; 56: 407-10.
72. Mehrabi MR, Haslmayer P, Humpeler S, Strauss-Blasche G, Marktl W, Tamaddon F, et al. Quantitative analysis of peroxisome proliferator-activated receptor γ (PPARγ) expression in arteries and hearts of patients with ischemic or dilated cardiomyopathy. Eur J Heart Fail 2003; 5: 733-9.
73. Yue T, Chen J, Bao W, Narayanan PK, Bril A, Jiang W, et al. In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-γ agonist rosiglitazone. Circulation 2001; 104: 2588-94.
74. Khandoudi N, Delerive P, Berrebi-Bertrand I, Buckingham RE, Staels B, Bril A. Rosiglitazone, a peroxisome proliferator-activated receptor-γ, inhibits the Jun NH(2)-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury, Diabetes 2002; 51: 1507-14.
75. Wayman NS, Hattori Y, McDonald MC, Mota-Filipe H, Cuzzocrea S, Pisano B, et al. Ligands of the peroxisome proliferator-activated receptors (PPAR-γ and PPAR-α) reduce myocardial infarct size. FASEB J 2002; 16: 1027-40.
76. Zhu P, Lu L, Xu Y, Schwartz GG. Troglitazone improves recovery of left ventricular function after regional ischemia in pigs. Circulation 2000; 101: 1165-71.
77. Shiomi T, Tsutsui H, Hayashidani S, Suematsu N, Ikeuchi M, Wen J, et al. Pioglitazone, a Peroxisome proliferator-activated receptor-γ agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 2002; 106: 3126-32.
78. Ghazzi MN, Perez JE, Antonucci TK, Driscoll JH, Huang SM, Faja BW, et al. Cardiac and glycemic benefits of troglitazone treatment in NIDDM. Diabetes 1997; 46: 433-9.
79. Tang WH, Francis GS, Hoogwerf BJ, Young JB. Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure. J Am Coll Cardiol 2003; 41: 1394-8.
80. Asakawa M, Takano H, Nagai T, Uozumi H, Hasegawa H, Kubota N, et al. Peroxisome proliferator-activated receptor γ plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. Circulation 2002; 105: 1240-6.
81. Yamamoto K, Ohki R, Lee RT, Ikeda U, Shimada K. Peroxisome proliferator-activated receptor γ activators inhibit cardiac hypertrophy in cardiac myocytes. Circulation 2001; 104: 1670-5.
82. Zou Y, Takano H, Akazawa H, Nagai T, Mizukami M, Komuro I. Molecular and cellular mechanisms of mechanical stress-induced cardiac hypertrophy. Endocr J 2002; 49: 1-13.
83. Kovacic-Milivojevic B, Gardner DG. Divergent regulation of the human atrial natriuretic peptide gene by c-jun and c-fos. Mol Cell Biol 1992; 12: 292-301.
84. Lee M-E, Bloch KD, Clifford JA, Quertermous T. Functional analysis of the endothelin-1 gene promoter. J Biol Chem 1990; 265: 10446-50.
85. Kunisada K, Tone E, Fujio Y, Matsui H, Yamauchi-Takihara K, Kishimoto T. Activation of gp130 transduces hypertrophic signals via STAT3 in cardiac myocytes. Circulation 1998; 98: 346-52.
86. Herzig TC, Jobe SM, Aoki H, Molkentin JD, Cowley AW Jr, Izumo S, et al. Angiotensin II type1a receptor gene expression in the heart: AP-1 and GATA-4 participate in the response to pressure overload. Proc Natl Acad Sci USA 1997; 94: 7543-8.
87. Hasegawa K, Lee SJ, Jobe SM, Markham BE, Kitsis RN. cis-Acting sequences that mediate induction of β-myosin heavy chain gene expression during left ventricular hypertrophy due to aortic constriction. Circulation 1997; 96: 3943-53.
88. Morimoto T, Hasegawa K, Kaburagi S, Kakita T, Wada H, Yanazume T, et al. Phosphorylation of GATA-4 is involved in α1-adrenergic agonist-responsive transcription of the endothelin-1 gene in cardiac myocytes. J Biol Chem 2000; 275: 13721-6.
89. De Keulenaer GW, Wang Y, Feng Y, Muangman S, Yamamoto K, Thompson JF, et al. Identification of IEX-1 as a biomechanically controlled nuclear factor-κB target gene that inhibits cardiomyocyte hypertrophy. Circ Res 2002; 90: 690-6.
90. Hirotani S, Otsu K, Nishida K, Higuchi Y, Morita T, Nakayama H, et al. Involvement of nuclear factor-κB and apoptosis signal-regulated kinase 1 in G-protein-coupled receptor agonist-induced cardiomyocyte hypertrophy. Circulation 2002; 105: 509-15.
91. Maruyama S, Kato K, Kodama M, Hirono S, Fuse K, Nakagawa O, et al. Fenofibrate, a peroxisome proliferator-activated receptor α activator, suppresses experimental autoimmune myocarditis by stimulating the interleukin-10 pathway in rats. J Atheroscler Thromb 2002; 9: 87-92.
92. Toyozaki T, Saito T, Shiraishi H, Tsukamoto Y, Takano H, Nagai T, et al. Macrophage inflammatory protein-1α relates to the recruitment of inflammatory cells in myosin-induced autoimmune myocarditis in rats. Lab Invest 2001; 81: 929-36.
93. Yuan Z, Liu Y, Liu Y, Zhang J, Kishimoto C, Wang Y, et al. Peroxisome proliferation-activated receptor-γ ligands ameliorate experimental autoimmune myocarditis. Cardiovasc Res 2003; 59: 685-94.
94. Watanabe K, Sekiya M, Tsuruoka T, Funada J, Kameoka H. Effect of insulin resistance on left ventricular hypertrophy and dysfunction in essential hypertension. J Hypertens 1999; 17: 1153-60.
95. Paternostro G, Pagano D, Gnecchi-Ruscone T, Bonser RS, Camici PG. Insulin resistance in patients with cardiac hypertrophy. Cardiovasc Res 1999; 42: 246-53.
96. De Souza W, Basic cell biology of Trypanosoma cruzi. Curr Pharm. Design 2002; 8(4): 269-85.
97. Naldini A, Pucci A, Bernini C, Carraro F. Regulation of angiogenesis by Th1- and Th2-type cytokines. Curr Pharm Design 2003; 9(7): 511-9.
98. Takano H, Ohtsuka M, Akazawa H, Toko H, Harada M, Hasegawa H, et al. Pleiotropic effects of cytokines on acute myocardial infarction: G-CSF as a novel therapy for acute myocardial infarction. Curr Pharm Design 2003; 9(14): 1121-7.